Bloomberg News

Roche Says Phase II MS Study Showed Disease Reduction

October 20, 2011

Oct. 20 (Bloomberg) -- Roche said that a Phase II study showed its ocrelizumab drug maintained significant reduction in disease activity for multiple sclerosis patients for almost two years.

Phase III trials are underway to investigate ocrelizumab in two forms of MS, the company said in an e-mailed statement.

To contact the editor responsible for this story: Leigh Baldwin at

Toyota's Hydrogen Man
blog comments powered by Disqus